90035-20-4

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-TRIFLUOROMETHYL-PHENOXY)-BENZALDEHYDE is utilized as a building block in organic synthesis for the production of pharmaceuticals. Its unique structure contributes to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(4-TRIFLUOROMETHYL-PHENOXY)-BENZALDEHYDE serves as a key component in the synthesis of agrochemicals, aiding in the creation of effective compounds for agricultural applications.
Used in Material Science:
4-(4-TRIFLUOROMETHYL-PHENOXY)-BENZALDEHYDE is also studied for its potential use in the development of new materials, capitalizing on its chemical characteristics to enhance material properties in various industries.
Used as a Reagent in Chemical Reactions:
4-(4-TRIFLUOROMETHYL-PHENOXY)-BENZALDEHYDE functions as a reagent in chemical reactions, facilitating specific transformations and syntheses, which are essential in advanced organic chemistry research and industrial processes.

InChI:InChI=1/C14H9F3O2/c15-14(16,17)11-3-7-13(8-4-11)19-12-5-1-10(9-18)2-6-12/h1-9H

Upstream product

• 402-45-9 4-hydroxybenzotrifluoride 
• 555-16-8 4-nitrobenzaldehdye 
• 128796-39-4 4-trifluoromethylphenylboronic acid 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 39634-42-9 p-[4-(trifluoromethyl)phenoxy]phenol 
• 592508-74-2 C₁₆H₁₃F₃O₂ 
• 209809-35-8 4-(4-trifluoromethylphenoxy)-2-propylphenol 
• 592508-49-1 hydroxy-(4-{3-[2-propyl-4-(4-trifluoromethyl-phenoxy)-phenoxy]-propoxy}-phenyl)-acetic acid methyl ester 
• 656235-20-0 2-imino-5-(4-{3-[2-propyl-4-(4-trifluoromethyl-phenoxy)-phenoxy]-propoxy}-phenyl)-thiazolidin-4-one 
• 179056-34-9 cycloheptyl-[4-(4-trifluoromethyl-phenoxy)-benzyl]-amine 
• 1201663-83-3 N-(4-fluorobenzyl)-1-(4-(4-(trifluoromethyl)phenoxy)phenyl)methanamine 
• 117114-01-9 4-(4'-trifluoromethylphenoxy)-benzyl bromide 

Relevant academic research and scientific papers

Pyrimidine onium compound and application thereof

The invention relates to a pyrimidine onium compound, nitride oxides, salt of the nitride oxides and a composition comprising the compound. The invention further relates to an application of the compound to plant pest control.

Highly efficient heterogeneous copper-catalysed O-arylation of phenols by nitroarenes leading to diaryl ethers

The heterogeneous O-arylation of phenols by nitroarenes was achieved in DMF at 100 °C by using an MCM-41-immobilised bidentate nitrogen copper(II) complex [MCM-41-2N-Cu(OAc)2] as catalyst, yielding a variety of unsymmetrical diaryl ethers in good to excellent yields. This heterogeneous copper catalyst can be easily prepared by a simple procedure from commercially readily available and inexpensive reagents, recovered by filtration of the reaction solution and recycled at least seven times without significant loss of activity.

Synthesis and Structure-Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6 S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazine (PA-824)

Novel extended side chain nitroimidazooxazine analogues featuring diverse linker groups between two aryl rings were studied as a potential strategy to improve solubility and oral activity against chronic infection by Mycobacterium tuberculosis. Both lipop

Ligand-free copper-catalyzed O-arylation of nitroarenes with phenols

The first example of ligand-free copper-catalyzed O-arylation of nitroarenes with phenols was developed, achieving unsymmetrical diaryl ethers in moderate to excellent yields. This arylation proceeded smoothly without promotion of the ligands, and displayed great functional group compatibility. Thus, the method represents a new, facile, and cost-effective approach to access unsymmetrical diaryl ethers.

The coupling of arylboronic acids with nitroarenes catalyzed by rhodium

The coupling of arylboronic acids with electron-deficient nitroarenes was realized for the first time by using a rhodium(I) catalyst under an air atmosphere, achieving unsymmetrical diaryl ethers with yields ranging from poor to good. From a deuterium labeling experiment, the oxygen atom is derived from ambient water. The efficiency of this reaction was demonstrated by its compatibility with fluoro, bromo, chloro, and trifluoromethyl groups.

THIAZOLE COMPOUNDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE

Disclosed are compounds of formula (I) wherein R1 and R2 are independently selected from hydrogen, halo, C1-4alkyl, C1-4alkoxy, CF3 and OCF3; -Y- represents formula (IA) R3 represents hydrogen, fluoro, chloro or C1-4alkyl; R4a and R4b each independently represent hydrogen, C1-4alkyl, C1-4alkoxy, CF3 or halo; and R5 represents a group Z-X; wherein Z is absent or represents (CH2)2 or O; and X represents formula (IB) wherein: J and L both represent CH, or one of J and L represents CH and the other represents N; when both J and L represent CH, R6 represents hydrogen, halo, CF3, C1-4alkyl or C1-4alkoxy in a meta or ortho position relative to the R7 substituent and R7 represents hydrogen, halo, CF3, OCF3, C1-4alkyl, C1-4alkoxy, CH2OH, CN, CONR8R9 or CO2H; or when one of J or L represents N, R6 represents hydrogen or halo in a meta or ortho position relative to the R7 substituent and R7 represents hydrogen, halo, CF3, C1-4alkyl, C1-4alkoxy, CH2OH, CN, CONR8R9 or CO2H; and R8 and R9 are independently selected from hydrogen and C1-4alkyl; or salts thereof which activate soluble guanylate cyclase (sGC), pharmaceutical compositions containing them, their use in medicine, and processes for their preparation.

2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS

Disclosed are compounds of formula (I) wherein R1 and R2 are independently selected from hydrogen, halo, CF3, C1-4alkyl and allyl; Y represents (II), (III), (IV) or (V) wherein R3 represents CF3 or C1-4alkyl; and R3a represents CF3 or C1-4alkyl.

HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS

The present invention provides compound of Formula (I): or a stereoisomer, tautomer, salt or solvate thereof, wherein the variables are defined herein. The compounds of formula (I) are inhibitors of Bcl-2 family antiapoptotic proteins, compositions containing the compounds and methods of treating diseases using the compounds.

5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists

A series of 5-aryl thiazolidine-2,4-diones containing 4-phenoxyphenyl side chains was designed, synthesized, and evaluated for PPAR agonist activities. One such compound 28 exhibited comparable levels of glucose correction to rosiglitazone in the db/db mouse type 2 diabetes animal model.